Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02701634 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)
A Phase 2 study, sponsored by Gilead Sciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 66
- Enrollment target
NCT02701634 is a Phase 2 study that was terminated before completion, run by Gilead Sciences. The registered enrollment target is 66 participants.
The verdict
NCT02701634, a Phase 2 study, was terminated before completion, sponsored by Gilead Sciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 66 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of entospletinib (ENTO) on the best overall response rate in adults with chronic graft versus host disease (cGVHD) who are currently receiving systemic corticosteroids as part of first-line therapy for cGVHD.
Interventions
- DRUG Placebo
- DRUG ENTO
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 66 participants |
| Start Date | 2016-05-27 |
| Est. Completion | 2018-03-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02701634
The ClinicalTrials.gov registry entry for NCT02701634 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 66 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02701634 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02701634 about?
NCT02701634 is a clinical study titled "Efficacy and Tolerability of Entospletinib in Combination With Systemic Corticosteroids as First-Line Therapy in Adults With Chronic Graft Versus Host Disease (cGVHD)". The primary objective of this study is to evaluate the effect of entospletinib (ENTO) on the best overall response rate in adults with chronic graft versus host disease (cGVHD) who are currently receiving systemic corticosteroids as part of first-line therapy for cGVHD.
What is the current status of trial NCT02701634?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 66 participants. The study started on 2016-05-27. Estimated completion is 2018-03-06.
What interventions are being tested in trial NCT02701634?
The interventions under investigation include: Placebo (DRUG), ENTO (DRUG).
Who is sponsoring clinical trial NCT02701634?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.